Effects of antifungal agents in sap activity of candida albicans isolates

Mycopathologia

Volumn 169, Issue 2, 2010, Pages 91-98

  Costa, Carolina Rodrigues ^a   Jesuíno, Rosália Santos Amorim ^a   de Aquino Lemos, Janine ^a   de Fátima Lisboa Fernandes, Orionalda ^a   e Souza, Lúcia Kioko Hasimoto ^a   Passos, Xisto Sena ^a   do Rosário Rodrigues Silva, Maria ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Candida albicans; Fluconazole; Sap activity; SAP genes; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; FLUCONAZOLE; FUNGAL DNA; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOUTH MUCOSA; POLYMERASE CHAIN REACTION;

ANTIFUNGAL AGENTS; ASPARTIC ACID PROTEASES; CANDIDA ALBICANS; CANDIDIASIS; CULTURE MEDIA; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOUTH MUCOSA; POLYMERASE CHAIN REACTION; PYRIMIDINES; TRIAZOLES;

BOVINAE; CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77649342273     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-009-9232-6     Document Type: Article

References (28)

1. Ghannoum MA. Candida: A causative agent of an emerging infection. J Investig Dermatol Symp Proc. 2001; 6: 188-96.
2. Nucci M, Kieren AM. Emerging fungal diseases. Clin Infect Dis. 2005; 41: 521-6.
3. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol. 2001; 39: 303-13.
4. Lan CY, Newport G, Murillo LA, Jones T, Sherer S, Davis RW, et al. Metabolic specialization associated with phenotypic switching in Candida albicans. PNAS. 2002; 99: 14907-12.
5. Naglik JR, Albrecht A, Bader O, Hube B. Candida albicans secreted aspartyl proteinase and host/pathogen interactions. Cel Microbiol. 2004; 6: 915-26.
6. Jin Y, Samaranayake YH, Yip HK, Samaranayake LP. Characterization of switch phenotypes in Candida albicans biofilms. Mycopathologia. 2005; 160: 191-200.
7. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003; 67: 400-28.
8. Schaller M, Borelli C, Korting HC, Hube B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses. 2005; 48: 365-77.
9. Stehr F, Felk A, Kretschmar M, Schaller M, Schäfer W, Hube B. Extracellular hydrolytic enzymes and their relevance during Candida albicans infections. Mycoses. 2000; 2: 17-21.
10. Lipp HP. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses. 2008; 51: 7-18.
11. Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect. 2004; 10: 86-95.
12. Burgess DS, Hastings RW, Summers KK, Hardin TC, Rinaldi MG. Pharmacodynamics of fluconazole, itraconazole and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis. 2000; 36: 13-8.
13. Li Y, Nguyen MH, Derendorf H, Cheng S, Clancy CJ. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography. Antimicrob Agents Chemother. 2007; 51: 2985-7.
14. Pfaller MA, Diekema DJ, Messe SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1. 586 recent clinical isolates of Candida species determined by broth microdilution disk diffusion and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001. J Clin Microbiol. 2003; 41: 1440-6.
15. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91: 317-21.
16. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase, a virulence factor by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother. 2000; 44: 1200-8.
17. Kurtzman CP, Fell JW. The yeast, a taxonomic study. 4th ed. Amsterdam: Elsevier; 1998.
18. CLSI-Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. Document M27-S3, CLSI, Pennsylvania, 19087, 2008; 28: 1-24.
19. Crandall M, Edwards JEJR. Segregation of proteinase-negative mutants from heterozygous Candida albicans. J Gen Microbiol. 1987; 133: 2817-24.
20. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretative breakpoints. J Clin Microbiol. 2006; 44: 819-26.
21. Del Poeta M, Toffaletti DL, Rude TH, Dykstra CC, Heitman J, Perfect JR. Topoisomerase I is essential in Cryptococcus neoformans: role in pathology and as an antifungal target. Genetics. 1999; 152: 176-8.
22. Casali AK, Goulart L, Silva LKR, Ribeiro AM, Amaral AA, Alves SH, et al. Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res. 2003; 33: 405-15.
23. Kalkanci A, Bozdayi G, Biri A, Kustimur S. Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP specific primers in Candida albicans isolates. Folia Microbiol. 2005; 50: 409-13.
24. Lian CH, Liu WD. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses. 2007; 50: 383-90.
25. Koga-Ito CY, Lyon JP, Vidotto V, Resende MA. Virulence factors and antifungal susceptibility of Candida albicans isolates from oral candidosis patients and control individuals. Mycopathologia. 2006; 161: 219-23.
26. Cannon RD, Fischer FJ, Niimi K, Niimi M, Arisawa M. Drug pumping mechanisms in Candida albicans. Jpn J Med Mycol. 1998; 39: 73-8.
27. Schaller M, Schäfer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol. 1998; 29: 605-15.
28. Naglik JR, Newport G, White TC, Fernandes-Naglik LL, Greenspan JR, Greenspan D, et al. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect Immun. 1999; 67: 2482-90.